Chronic pain
20 research papers currently available
Medical Cannabis Research Library
Chronic non-cancer Pain
Mark A. Ware, Tongtong Wang, Stan Shapiro, Jean-Paul Collet Et Al.
The Journal of Pain,
2015
Prospective cohort study for safety. 1-year follow-up. 7 clinical centers across Canada
Whole plant extract
12.5% THC
Link to publicationChronic neuropathic pain
Ware MA1, Wang T, Shapiro S, Robinson A, Et Al.
Canadian Medical Association Journal,
2010
Randomized, double-blind, placebo-controlled, four period (each 14 days) crossover design
Whole plant extract
2.5%, 6.0% and 9.4% THC (inhaled)
Link to publicationAdvanced cancer patients with chronic pain unalleviated by optimized opioid therapy
Fallon MT, Albert Lux, McQuade, Rossetti Et Al.
British Journal of Pain,
2017
Phase 3, double-blind, randomized, placebo-controlled trials. N = 399
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationFibromyalgia
Habib G, Artul S
Journal of Clinical Rheumatology,
2018
Open study. N= 26
Whole plant extract
Various
Link to publicationAdvanced cancer and opioid-refractory pain
Portenoy RK1, Ganae-Motan ED, Allende S, Yanagihara R Et. Al
Journal of Pain,
2012
Randomized, double-blind, placebo-controlled, graded-dose study looking at efficacy and safety at varying doses of Sativex. N = 263
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationChemotherapy-Induced Neuropathic Pain
Lynch ME, Cesar-Rittenberg P, Hohmann AG.
Journal of Pain and Symptom Management,
2014
A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMigraine, headache, arthritis, and chronic pain
Eric P. Baron, Philippe Lucas, Joshua Eades and Olivia Hogue
The Journal of Headache and Pain,
2018
Uncontrolled Electronic survey
Various
Various
Link to publicationAdvanced Cancer - Palliative Care / Appetite / Pain
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.
Journal of Pain and Symptom Management,
2015
Observational one year study n = 279
Various
Various
Link to publicationChronic non-cancer Pain
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study
Lancet Pubic Health,
2018
4-year prospective cohort study
Various
Various
Link to publicationAdvanced Cancer Patients with Chronic Uncontrolled Pain
Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, Marie T. Fallon.
Journal of Pain and Symptom Management,
2018
Phase 3, double-blind, randomized, placebo-controlled trials. N = 399
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationFibromyalgia
Ware MA, Fitzcharles MA, Joseph L, Shir Y.
Anesthesia & Analgesia,
2010
Single centre, randomized, double-blind, active-control, equivalency crossover trial to compare nabilone to amitriptyline
Sythetic THC
0.5-1.0 mg
Link to publicationFibromyalgia
Fiz J, Durán M, Capellà D, Carbonell J, Farré M.
PLOS One,
2011
Uncontrolled study n = 56 (MC users vs non-users)
Various
Various
Link to publicationFibromyalgia
Habib G, Artul S.
Journal of Clinical Rheumatology,
2018
Uncontrolled study Biased selection identified from Israel Hospital registries. n = 26
Various
Various
Link to publicationFibromyalgia
Skrabek RQ, Galimova L, Ethans K, Perry D.
Journal of Pain,
2008
Randomized, parallel, double-blind, placebo-controlled trial n = 40
Sythetic THC
Nabilone THC
Link to publicationStudy of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt & S. Ratcliffe
Journal of Neurology,
2012
A double-blind, randomized, placebo-controlled, parallel-group
Cannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study
Johnson et al.
Journal of Pain and Symptom Management,
2010
Double-blind, Randomized, Placebo-Controlled Study.
Cannabis in Palliative Medicine
G.T. Carter et al.
American Journal of Hospice and Palliative Medicine,
2011
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids
Nielsen et al.
The Lancet,
2018
Clinical Endocannabinoid Deficiency Reconsidered
E.B. Russo
Cannabis and Cannabinoid Research,
2016
Spasticity in MS
W Notcutt, R Langford, P Davies
Multiple Sclerosis Journal,
2013
Placebo-controlled, parallel-group, randomized withdrawal study
THC/CBD Extract
2.7 mg THC and 2.5 mg CBD per 100 microlitre Spray (oral buccal spray)
Link to publicationNeuropathic pain in MS patients
Russo M, Naro A, Leo A, Sessa E, Et Al.
Pain Medicine,
2016
Specific clinical and neurophysiological assessment
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationNeuropathic pain associated with multiple sclerosis
Rog DJ, Nurmikko TJ, Young CA
Clinical Therapeutics,
2007
Uncontrolled, open-label trial extension sudy from 5 week initial RCT. 2 years. N = 28/64.
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationCentral pain in multiple sclerosis
Rog DJ, Nurmikko TJ, Friede T, Young CA
Neurology,
2005
Randomized, double-blind, placebo-controlled, parallel-group trial. 5 weeks study. N = 64
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis-Induced Neuropathic Pain
Turcotte D, Doupe M, Torabi M, Gomori A, Et Al.
Pain Medicine,
2015
A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15
Sythetic THC
2.7 µmol oral
Stable MS and muscle spasticity (short term)
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Et. Al
Lancet,
2003
Multicenter, randomized, placebo-controlled trial. n = 630. Short term - 15 weeks
Sythetic THC
2.5 mg oral capsule
Link to publicationStable MS and muscle spasticity (extension study)
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Et. Al
Journal of Neurology, Neurosurgery, and Psychiatry,
2005
Multicenter, randomized, placebo-controlled trial. n =502. Extension (longer term) study - 12 months.
Whole plant extract
"2·5 mg of 9-THC equivalent, 1·25 mg of CBD, < 5% other cannabinoids / capsule "
Link to publicationMultiple Sclerosis (spasticity, spasms, bladder problems, tremor and pain)
Wade DT1, Makela P, Robson P, House H, Bateman C.
Multiple Sclerosis Journal,
2004
A parallel group, double-blind, randomized, placebo-controlled study. N = 160
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis and spasticity
Wade DT, Makela PM, House H, Bateman C, Robson P.
Multiple Sclerosis,
2006
Open-label trial (Average 434 days) following a 10-week, placebo-controlled study. n = 137
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationSpasticity caused by multiple sclerosis.
C. Collin P. Davies, Et Al. for the Sativex Spasticity in MS Study Group
European Journal of Neurology,
2007
Randomized controlled trial n = 189
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis and spasticity
Serpell MG, Notcutt W, Collin C.
Journal of Neurology,
2013
Six-week randomised controlled trial
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationRefractory MS-associated spasticity
Novotna A, Mares J, Ratcliffe S, Novakova I, Et Al.
European journal of neurology,
2011
Phase 3 randomized, double-blind, placebo-controlled, parallel-group, enriched-design study. 4 week selection leading to 12 week longer study
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis and muscles stiffness
Zajicek JP, Hobart JC, Slade A, Et Al.
J Neurol Neurosurg Psychiatry,
2012
Multicentre, double-blind, placebo-controlled, phase III study. 12 week study. N = 279
Multiple Sclerosis - Tremor
Fox P, Bain PG, Glickman S, Carroll C, Zajicek J.
Neurology,
2004
Randomized double-blind placebo-controlled crossover trial. N = 14
Whole plant extract
Not stated
Link to publicationMultiple Sclerosis
Susan Ball, Jane Vickery, Jeremy Hobart, Dave Wright, Colin Green, James Shearer, Andrew Nunn, Mayam Gomez Cano, David MacManus, David Miller, Shahrukh Mallik, and John Zajicek
Health Technology Assessment,
2015
Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial
Sythetic THC
THC Only. Oral. Max 28mg/ml / day
Link to publicationMultiple Sclerosis
R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt, S. Ratcliffe
Journal of neurology,
2013
Phase III double-blinded, placebo-controlled parallel group study
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis-Induced Neuropathic Pain
Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M.
Pain Medicine,
2015
A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15
Sythetic THC
2.7 µmol oral
Link to publicationStudy of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt & S. Ratcliffe
Journal of Neurology,
2012
A double-blind, randomized, placebo-controlled, parallel-group
Cannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Efficacy and safety of medical marijuana in selected neurologic disorders
Koppel et al.
American Academy of Neurology,
2014
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
D.J.Rog et al.
Neurology,
2005
Double-blind, Randomized, Placebo-Controlled Study.
A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols
Novotna et al.
European journal of neurology,
2011
Phase 3, double-blind, randomized, placebo-controlled trial
Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
J.P. Zajicek et al.
Multiple sclerosis Research paper,
2012
Phase 3, double-blind, randomized, placebo-controlled trial
Pediatric epilepsy
Press CA, Knupp KG, Chapman KE.
Epilepsy & Behaviour,
2015
Open label retrospective uncontrolled study. N = 19
Unstated. Various
Link to publicationEpilepsy
Hausman-Kedem M, Menascu S, Kramer U
Brain Development,
2018
Observational uncontrolled study. N = 57. Min 3 months.
Whole plant extract
CBD/THC ratio of 20:1. (Average CBD dose 11.4 mg/kg/d). Oil
Link to publicationPediatric epilepsy (treatment resistant)
Porter BE, Jacobson C
Epilepsy & Behaviour,
2013
A retrospective uncontrolled study. N = 75
Unstated
Cannabidiol enriched - varied. (From CBD < 0.5 mg/kg/day - 28.6 mg/kg/day; THC 0 to 0.8mg/kg/day)
Link to publicationPediatric epilepsy
Treat L, Chapman KE, Colborn KL, Knupp KG
Epilepsia,
2017
Retrospective chart review. Uncontrolled. N = 119
Whole plant extract
Oral various. Undefined
Link to publicationRefractory Epilepsy
Aguirre-Velázquez CG
Neurology Research International,
2017
Uncontrolled retrospective study. N = 53
Various
Varied. CBD 5000 mg /CBD 1000 mg, CBD + THC 5000mg/CBD + THC 500mg/ Other CBD/THC
Link to publicationDravet Syndrome
Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir1 Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III
Annals of Clinical and Translational Neurology,
2018
Whole plant extract
100mg CBD : 2 mg THC (TIL-TC150)
Link to publicationDravet Syndrome
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S
New England Journal of Medicine,
2017
A multinational, randomized, double-blind trial. N = 120. 14 week treatment
Whole plant extract
CBD only (20 mg/kg bw) oral
Link to publicationTreatment-resistant epilepsy
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S5, Singhal NS, Wilson CA, Patel A, Cilio MR.
Lancet Neurology,
2016
Open-label uncontrolled interventional trial
Whole plant extract
CBD only (2.5-25/50 mg/kg bw) oral
Link to publicationLennox-Gastaut syndrome
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group
New england journal of medicine,
2018
Double-blind, placebo-controlled trial. 14 weeks. N =225
Whole plant extract
CBD only (10 or 25 mg/kg bw) oral
Link to publicationLennox-Gastaut syndrome
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group.
Lancet,
2018
Whole plant extract
CBD only (20 mg/kg bw) oral
Link to publicationPediatric epilepsy
Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B.
Seizure,
2016
Retrospective uncontrolled study. N = 74
Whole plant extract
20 CBD : 1 THC
Link to publicationEpilepsy
Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R
Pharmacology,
1980
Double-blind, placebo-controlled trial. N = 15. Up to 4.5 months
Whole plant extract
CBD (200-300mg)
Link to publicationCannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky et al
The New England Journal of Medicine,
2017
Double-blind, Randomized, Placebo-Controlled Study.
Cannabis for pediatric epilepsy: protocol for a living systematic review
McCoy B et al.
Systematic Reviews,
2018
Efficacy and safety of medical marijuana in selected neurologic disorders
Koppel et al.
American Academy of Neurology,
2014
CINV
Br J Clin Pharmacol
British Journal of Clinical Pharmacology,
2010
Pilot, randomized, double-blind, placebo-controlled phase II clinical trial assessing tolerability, preliminary efficacy, and pharmacokinetics of Whole plant medicine in conjuction with standard treatment. N = 16
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
CINV
Lane M, Vogel CL, Ferguson J, Krasnow S, Et Al.
Journal of Pain and Symptom Management,
1991
Randomized, double-blind, parallel group, multicenter study. Assessing combination treatment of Dronabinol and prochlorperazine
Sythetic THC
2.5% THC oil
Link to publicationDelayed CINV
Meiri E, Jhangiani H, Vredenburgh JJ, Et Al.
Current Medical Research and Opinion,
2007
Randomized, double blinded, placebo- controlled parallel group 5 day trial n = 64
Sythetic THC
2.5 mg oral capsule
Link to publicationCINV
Duran M, Pérez E, Abanades S, Vidal X, Et Al.
British Journal of Clinical Pharmacology,
2010
Pilot, randomized,double-blind, placebo-controlled phase II clinical trial. N = 16
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationNausea and Vomiting in Peritoneal Carcinomatosis (unrelated to Chemotherapy)
Sarah L Hernandez, Inna Shayner, Karen T Stover, Et Al.
American Journal of Hospice and Palliative Medicine,
2013
Case study (Pt with end-stage ovarian cancer with peritoneal carcinomatosis and refractory nausea and vomiting)
Sythetic THC
2.5 mg oral capsule
Link to publicationCINV
Sutton IR, Daeninck P
The Journal of Supportive Oncology,
2006
Survey; Uncontrolled case reports. 1. Refractory CINV and 2. Intractable Pain
Sythetic THC
2.5 mg oral capsule
Link to publicationCINV
Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller
Evidence-Based Complementary and Alternative Medicine,
2013
Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)
Various
Various
Link to publicationCINV
Steven M. Grunberg, Mark F. Munsell, Phuong Khanh H. Morrow, Jeffrey Kent Giguere, Ulla Jo Ule, Steven J. Saccaro, Adedayo A. Onitilo, Joanna K. Metzner-Sadurski, Michael Fisch
Journal of Clinical Oncology,
2012
Randomized double-blind study. N = 62
Synthetic Cannabinoid
5mg Synthetic Cannabinoid
Link to publicationDelta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients
T. D. Brisbois et. al
Annals of Oncology,
2011
double-blind, placebo-controlled pilot trial
2.5mg THC or placebo oral capsules
Link to publicationCannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Advanced Cancer Patients with Chronic Uncontrolled Pain
Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti Et Al.
Journal of Pain and Symptom Management,
2018
Double-blind, Randomized, Placebo-Controlled Study.
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationPallative care cancer patients
Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller
Evidence-Based Complementary and Alternative Medicine,
2013
Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)
Various
Various
Link to publicationTerminal Cancer-Related Pain (Moderate / Severe) Refractory to Strong Opioid Analgesics
Johnson JR1, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Et Al.
Journal of Pain and Symptom Management,
2010
Two-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial (GW Pharma Ltd). N= 177
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationTerminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.
Journal of Pain and Symptom Management,
2013
Open-Label Extension Study from original 2 week RCT study. N = 43.
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationChemotherapy-Induced Neuropathic Pain
Lynch ME, Cesar-Rittenberg P, Hohmann AG.
Journal of Pain and Symptom Management,
2014
A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationAdvanced Cancer - Palliative Care / Appetite / Pain
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.
Journal of Pain and Symptom Management,
2015
Observational one year study n = 279
Various
Various
Link to publicationFibromyalgia
Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R.
Current Medical Research and Opinion,
2006
Uncontrolled pilot sudy (n= 9)
Unstated
2.5-15 mg of delta-9-THC
Cancer Pain / Palliative
Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT
Journal of Pain,
2012
Randomized, placebo-controlled, graded-dose trial. N = 360
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationDelta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients
T. D. Brisbois et. al
Annals of Oncology,
2011
double-blind, placebo-controlled pilot trial
2.5mg THC or placebo oral capsules
Link to publicationCannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Characterization of Chemosensory Alterations in Advanced Cancer Reveals Specific Chemosensory Phenotypes Impacting Dietary Intake and Quality of Life
Brisbois et al.
Journal of Pain and Symptom management.,
2011
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study
Johnson et al.
Journal of Pain and Symptom Management,
2010
Double-blind, Randomized, Placebo-Controlled Study.
Treatment of cancer pain
R.K Portenoy et al.
The Lancet,
2011
Double-blind, Randomized, Placebo-Controlled Study.
Refractory human diabetic peripheral neuropathic pain (DPN)
Toth C, Mawani S, Brady S, Chan C, Liu C, Et Al.
Pain,
2012
Single-center, randomized, double-blind, placebo-controlled, flexible-dose study with an enriched enrollment randomized withdrawal design.
Sythetic THC
2.7 µmol oral
Link to publicationNeuropathic pain (Pts with peripheral neuropathy)
Bestard JA, Toth CC.
Pain Practice,
2011
Open‐Label Comparison Trial to compare the efficacy of nabilone as either monotherapy or adjuvant therapy with a first‐line medication (gabapentin)
Sythetic THC
2.7 µmol oral
Link to publicationChronic neuropathic pain
Ware MA1, Wang T, Shapiro S, Robinson A, Et Al.
Canadian Medical Association Journal,
2010
Randomized, double-blind, placebo-controlled, four period (each 14 days) crossover design
Whole plant extract
2.5%, 6.0% and 9.4% THC (inhaled)
Link to publicationNeuropathic pain in MS patients
Russo M, Naro A, Leo A, Sessa E, Et Al.
Pain Medicine,
2016
Specific clinical and neurophysiological assessment
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationNeuropathic pain associated with multiple sclerosis
Rog DJ, Nurmikko TJ, Young CA
Clinical Therapeutics,
2007
Uncontrolled, open-label trial extension sudy from 5 week initial RCT. 2 years. N = 28/64.
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationMultiple Sclerosis-Induced Neuropathic Pain
Turcotte D, Doupe M, Torabi M, Gomori A, Et Al.
Pain Medicine,
2015
A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15
Sythetic THC
2.7 µmol oral
Neuropathic Pain (central and peripheral)
Wilsey B1, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H.
The Journal of Pain,
2013
Randomized, double-blind, placebocontrolled, crossover design. N = 39
Whole Plant Extract (Vapourised)
medium-dose (3.53% THC), low-dose (1.29% THC)
Link to publicationChemotherapy-Induced Neuropathic Pain
Lynch ME, Cesar-Rittenberg P, Hohmann AG.
Journal of Pain and Symptom Management,
2014
A randomized, double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension. N = 16
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationNeuropathic Pain in HIV (HIV-associated distal sensory predominant polyneuropathy (DSPN)
Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Et. Al
Neuropsychopharmacology,
2009
Phase II, double-blind, placebo-controlled, crossover trial assessing analgesia with smoked cannabis in HIV-associated distal sensory predominant polyneuropathy (DSPN). N =28
Whole plant extract
THC strengths ranging 1% - 8% conc by weight. CBD not reported. Smoked
Link to publicationMultiple Sclerosis-Induced Neuropathic Pain
Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M.
Pain Medicine,
2015
A single center, randomized, double-blinded, parallel, placebo-controlled study assessing Nabilone combined with Gabapentin . N = 15
Sythetic THC
2.7 µmol oral
Link to publicationNeurogenic pain
Derick T Wade, Philip Robson,Petra Makela and Julia Aram
Clinical Rehabilitation,
2003
Pilot double-blind cross-over study. N = 20
Whole plant extract
2.5mg THC : 2.5mg CBD sublingual spray
Link to publicationNeuropathic Pain
R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt, S. Ratcliffe
Journal of neurology,
2013
Phase III double-blinded, placebo-controlled parallel group study
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationPeripheral Neuropathic Pain
Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E
European Journal of Pain,
2014
Phase III double-blinded, placebo-controlled parallel group study
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationAn Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy
J. A. Bestard
Pain Practice,
2010
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids
Nielsen et al.
The Lancet,
2018
Parkinson's Disease
Itay Lotan; Therese A. Treves; Yaniv Roditi; Ruth Djaldetti
Clinical Neuropharmacology,
2014
Uncontrolled. Open label n = 22
Smoked cannabis
0.5 g cannabis
Link to publicationParkinson’s disease
Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V
Journal of Psychopharmacology,
2009
Open label case series n = 6
CBD (Undefined)
CBD only. Oral capsule
Link to publicationParkinson disease:
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP
Neurology,
2004
Randomized, double-blind, placebo-controlled crossover trial. N = 19
Whole plant extract
1.25 mg CBD and 2.5 mg THC
Parkinson's disease
Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y
Clinical Neuropharmacology,
2004
Randomized, double-blind, placebo-controlled trial. N = 8
Synthetic Cannabinoid
Selective central (CB1) cannabinoid receptor antagonist
Link to publicationParkinson's disease
Venderová K, Růzicka E, Vorísek V, Visnovský P
Movement Disorders,
2004
Uncontrolled questionnaire
Various
Various
Link to publicationParkinson's disease
Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA
Journal of Psychopharmacology,
2014
Exploratory randomized, double-blind, placebo-controlled trial n = 22.
Unstated
CBD 75 or 300 mg/day
Link to publicationParkinson's disease
Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM
Neurology,
2001
Randomized, double-blind, placebo-controlled, crossover trial. n = 7
Synthetic Cannabinoid
Not stated
Link to publicationCannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.
Journal of Clinical Pharmacy and Therapeutics,
2014
Case series n = 4
CBD (Undefined)
CBD only. Oral capsule
Link to publicationParkinson's disease
Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA.
Journal of Clinical Pharmacy and Therapeutics,
2014
Case series n = 4
CBD (Undefined)
CBD only. Oral capsule
Link to publicationEffects of cannabidiol in the treatment of patients with Parkinson’s disease
Chagas et al.
Journal of Psychopharmacology,
2014
Cancer-Related Anorexia-Cachexia Syndrome
Aminah Jatoi, Harold E. Windschitl, Charles L. Loprinzi, Jeff A. Sloan, Shaker R. Dakhil, James A. Mailliard, Sarode Pundaleeka, Carl G. Kardinal, Tom R. Fitch, James E. Krook, Paul J. Novotny, and Brad Christensen
Journal of Clinical Oncology,
2002
Multi-institutional, double-blind, randomized trial. N = 469
Synthetic Cannabinoid
2.5mg Capsule
Link to publicationCancer-related anorexia-cachexia syndrome (CACS)
Cannabis-In-Cachexia-Study-Group1, Strasser F, Luftner D, Possinger K Et. Al
JOURNAL OF CLINICAL ONCOLOGY,
2006
Multicenter, phase III, randomized, double-blind, placebo (PL)-controlled, three-arm, parallel study. N = 243
Whole plant extract
2.5 mg THC : 1 mg CBD capsules and 2.5 mg THC capsules
Link to publicationCancer- Cachexia
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.
Journal of Pain and Symptom Management,
2015
Observational one year study n = 279
Various
Various - uncontrolled
Link to publicationCancer-Related Anorexia
Walsh D, Kirkova J, Davis MP.
Journal of Pain and Symptom Management,
2005
Uncontrolled. Case Series
Various
Various Uncontrolled
Link to publicationDronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
J. E. Beal et al.
Journal of Pain and Symptom Management,
1995
multi-institutional study
2.5 mg dronabinol twice daily or placebo.
Link to publicationDelta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients
T. D. Brisbois et. al
Annals of Oncology,
2011
double-blind, placebo-controlled pilot trial
2.5mg THC or placebo oral capsules
Link to publicationImpact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients
A. Lahat et al.
Digestion,
2012
A Pilot Prospective Study
2.5mg THC or Placebo
Link to publicationPallative care cancer patients
Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, and Ella Muller
Evidence-Based Complementary and Alternative Medicine,
2013
Prospective, Observational Study. Interview questions and data collection. 6-8 week Tx. N= 106 (selected bias group continuing Tx)
Various
Various
Link to publicationPediatric palliative care
Michaela Kuhlen, Jessica I. Hoell, Gabriele Gagnon, Stefan Balzer
European Journal of Paediatric Neurology,
2016
Open, uncontrolled, retrospective study measuring value, efficacy, and safety
Synthetic
Dronabinol -Synthetic THC. 2.5% THC oil
Link to publicationTreatment resistant refractory spasticity in pediatric palliative care
Michaela Kuhlen , Jessica I. Hoell, Gabriele Gagnon, Et Al.
European Journal of Paediatric Neurology,
2016
Open, uncontrolled, retrospective study measuring value, efficacy, and safety. N=16. Median duration 181 days
Sythetic THC
2.5% THC oil
Link to publicationAdvanced Cancer - Palliative Care / Appetite / Pain
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I.
Journal of Pain and Symptom Management,
2015
Observational one year study n = 279
Various
Various
Link to publicationAdvanced Cancer Patients with Chronic Uncontrolled Pain
Aron H. Lichtman, Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, Marie T. Fallon,
Journal of Pain and Symptom Management,
2018
Phase 3 Double-Blind, Randomized, Placebo-Controlled Study. N=397. Self-titrated study medications over a two-week period, followed by a three-week treatment period at the titrated dose.
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationCancer Pain / Palliative
Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT
Journal of Pain,
2012
Randomized, placebo-controlled, graded-dose trial. N = 360
Whole plant extract
2.7 mg THC and 2.5 mg CBD per 100ul Oromucosal spray
Link to publicationPalliative Care
Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV.
Annals of Oncology ,
2011
Randomized, double-blind, placebo-controlled pilot trial. N = 46
Synthetic Cannabinoid
2.5 mg oral capsule
Link to publicationDronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
J. E. Beal et al.
Journal of Pain and Symptom Management,
1995
multi-institutional study
2.5 mg dronabinol twice daily or placebo.
Link to publicationCannabinoids for Medical Use
Whiting et al. 2015
Original Investigation,
2015
Cannabis‐based medicines for chronic neuropathic pain in adults
Mucke et al.
cochrane Systematic Review,
2018
Characterization of Chemosensory Alterations in Advanced Cancer Reveals Specific Chemosensory Phenotypes Impacting Dietary Intake and Quality of Life
Brisbois et al.
Journal of Pain and Symptom management.,
2011
Cannabis in Palliative Medicine
G.T. Carter et al.
American Journal of Hospice and Palliative Medicine,
2011
Chronic PTSD
Pablo Roitman, Raphael Mechoulam, Rena Cooper-Kazaz, Arieh Shalev
Clinical Drug Investigation,
2014
Pilot, open-label study on tolerance and safety. N = 10. THC as an add on Therapy
Synthetic
Oral
Link to publicationPTSD
Jetly R, Heber A, Fraser G, Boisvert D
Psychoneuroendocrinology,
2015
Randomized, double-blind, placebo-controlled cross-over design study. N = 10. 7-2-7 week study treatments
Sythetic THC
0.5mg-3 mg oral capsule
Link to publicationPTSD 1
Cameron C, Watson D, Robinson J
Journal of Clinical Psychopharmacology,
2014
Uncontrolled retroscpective study - patients at least a single dose of nabilone for any indication from January 1, 2010, to July 31, 2013 (n = 104)
Sythetic THC
Various - powder in water
Link to publicationPTSD and Substance Use Disorders
Ruglass LM, Shevorykin A, Radoncic V, Smith KM, Smith PH, Et Al.
Journal of Clinical Medicine,
2017
Uncontrolled study with Multivariate regression analyses and multilevel linear growth models
Whole plant extract
Various - uncontrolled
Link to publicationCannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
Bergamaschi et al
Neuropsychopharmacology,
2011
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder
Crippa et al.
Journal of Psychopharmacology,
2011
Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress
Childs et al.
Drug and Alcohol Dependence,
2017
Double-blind
THC
no THC, 7.5mg THC or 12.5mg THC
Link to publicationShort-term effects of cannabis consumption on cognitive performance in medical cannabis patients
Cutler et al.
Applied Neuropsychology: Adult,
2019
Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder
S. Shannon & J. Opila-Lehman
The Permanente Journal,
2016
Patient-Reported Symptom Relief Following Medical Cannabis Consumption
Stith et al
Frontiers in Pharmacol,
2018
Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems
Aran et al.
Journal of Autism and Development Disorders,
2018
A Retrospective Feasibility Study
1 THC; 20 CBD
Link to publicationCannabidiol as a suggested candidate for treatment of autism spectrum disorder
Schleider et al
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
2019
Real life Experience of Medical Cannabis Treatment in Autism
Schleider et al
Scientific reports,
2019
Retrospective study
30% CBD 1.5% THC
Link to publicationClinical Endocannabinoid Deficiency Reconsidered
E.B. Russo
Cannabis and Cannabinoid Research,
2016
Nabilone for the treatment of medication overuse headache
L.A. Pini et al.
Journal of Headache pain,
2012
The Use of Marijuana or Synthetic Cannabinoids for the Treatment of Headache
U. Napchan et al.
Headache,
2011
Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder
S. Shannon & J. Opila-Lehman
The Permanente Journal,
2016
An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy
Bestard and Toth
Pain Practice,
2010
Cannabis, Cannabinoids, and Sleep
Babson et al.
Current Psychiatry Reports,
2017
Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients
A. Lahat et al.
Digestion,
2012
A Pilot Prospective Study
2.5mg THC or Placebo
Link to publicationCannabis Induces a Clinical Response in Patients With Crohn's Disease
Naftali et al.
Clinical Gastroenterology and Hepatology,
2013
A Prospective Placebo-Controlled Study
THC
THC or placebo
Link to publicationReporting standards for studies of diagnostic test accuracy in dementia
Storr et al.
American Academy of Neurology,
2014
Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy
S.Pandey et al.
Complementary Therapies in Medicine,
2020
PLEASE READ THESE TERMS CAREFULLY
By registering as a health practitioner on greenchoices.com.au, you agree and consent to both the Terms of Use and the Privacy Policy as well as the additional terms and conditions below (“Practitioner Terms of Use”) in connection with your use of the Site and any Content, Functionality, products or services provided by the Providers, their Representatives or third parties. To the extent there is any inconsistency between these Practitioner Terms of Use and the Terms of Use or Privacy Policy, these Practitioner Terms of Use prevail. Expressions not defined in these terms and conditions are defined in the Green Choices Privacy Policy and Terms of Use.
The Providers reserve the right to amend these Practitioner Terms of Use at any time and your access and use of the Site following such amendment constitutes your acceptance of the amended Practitioner Terms of Use. Any changes will be published in this web document. Since following registration as a health practitioner on greenchoices.com.au you are bound by these Practitioner Terms of Use, please periodically refer to this web document to monitor changes.
If you have consented to GC displaying or advertising a clinical trial on the Site then you agree that the Providers provide any information you provide about the clinical trial and your name and contact details to the public, including through email and newsletters, and also to private and governmental third parties.
Any information or advice provided or displayed on the Site in connection with any products (including medicinal cannabis products) or services (including support or assistance with regulatory matters), supplied or provided by third parties or the Providers (“Products & Services”) is provided solely on an informational basis and, in the case of third party Products or Services, relying on information or advice received by the Providers from such third parties from time to time.
Any information (including any product information or consumer information) on Products & Services displayed on the Site is published on behalf of the relevant supplier of that Product or Service. Although reasonable efforts are made to ensure information and advice made available on the Site is from appropriate sources, you acknowledge that the Providers have not independently verified or confirmed the accuracy or appropriateness of any information or advice received from third parties or of any Products & Services provided by third parties. The Provider and its Representatives take no responsibility for such information and shall not be responsible for the continued currency of the information or for any errors, omissions or inaccuracies in such information whether arising from negligence or otherwise, or for any consequences arising therefrom.
You agree that the Providers may contact you to discuss whether you would like assistance from GC in connection with any GC Services.
You further acknowledge and agree that any request to view or understand any Product displayed on the Site has been made independently by you and that such request has not been solicited by the Providers, their Representatives or any supplier of that Product.
You acknowledge that, provided the product supplier has suggested or recommended that a product may be used for a particular condition, illness or disorder, that the Providers and the Site may select certain products within such group of products as priority responses to search terms you enter for that condition, illness or disorder.
To the maximum extent permitted by the Australian Consumer Law and all other applicable laws, you agree that you access and use the Site and its Content entirely at your own risk and that the Providers and their Representatives make no representations, and has no liability whatsoever, in connection with:
and you release, indemnify and hold harmless the Providers and their Representatives from any claim or liability whatsoever for any loss, cost, damage or expense whatsoever (including direct, indirect or consequential, punitive loss or special) that you or your patients may suffer in connection with the reliance on or use of such information or such Products and Services. The liability of the Providers for a breach of a non-excludable condition or consumer guarantee warranty in relation to any Services provided by the Providers is limited to re-supply of the Services.
Where you have provided consent to display your business phone number, email address, profession or company to the public directory, you consent to the Providers providing such information to the public, including through email or newsletter communications, and also to private and governmental third parties in connection with building information networks and registries of medical practitioners.
You acknowledge and agree that where you provide any personal information (including any sensitive information) concerning third parties (including your patients) to the Providers, via the Site or otherwise, that you are authorised to collect and disclose this information to the Providers and to permit the Providers to use that information in accordance with the Privacy Policy (as may be amended by these Practitioner Terms of Use);
Without limiting anything in the Terms of Use, you acknowledge and agree that to the extent you send, provide or upload any documentation or other brand names, logos, text, materials, graphics, links, or uploaded content, software and all other material (“Materials”) whatsoever that you are either the owner of those Materials or otherwise licensed to provide those Materials to the Providers and that you authorise the Providers to use such Materials as they see fit, including displaying on the Site or sharing with third parties. You indemnify the Providers and their Representatives against any claims from third parties arising from the Providers’ disclosure or use of those Materials.
Without limiting anything in the Terms of Use, you acknowledge and agree that all comments, feedback, suggestions, ideas, and other submissions disclosed, including your experience treating certain conditions with medicinal cannabis, how you have used medicinal cannabis to treat certain illnesses or conditions, and any successes or failures in treatment that you have experienced, on or by the Site or otherwise disclosed, submitted or offered in connection with your use of the Site (collectively, “Comments”) shall be and remain the Providers’ property and may used, shared and disclosed as the Providers see fit. Such disclosure, submission or offer of any Comments shall constitute an assignment to the Providers of all worldwide right, title and interest in all copyrights and other intellectual properties in the Comments. The Providers are and shall be under no obligation (a) to maintain any Comments in confidence; (b) to pay to user any compensation for any Comments; or (c) to respond to any user Comments.
You agree that none of the Comments submitted by you to the Site will violate any right of any third party, including copyright, trademark, privacy or other personal or proprietary right(s). You further agree that none of the Comments submitted by you to the Site will be or contain libellous or otherwise unlawful, abusive or obscene material. You are and shall remain solely responsible for the content of any Comments you make.
You agree that, other than may be expressly set out in these Practitioner Terms of Use or the Terms of Use, neither the Providers nor you are agents or representatives of each other.
Nothing contained on the Site grants or should be construed as granting, any license or right to use, implied or otherwise, any trademarks, trade names, service marks, trade dress, copyrighted or other proprietary material displayed on this Site without the prior written consent of the Providers or the owner of such material. All rights not expressly granted herein by the Providers to you are reserved by the Providers or their licensors. Third-party trade names, product names and logos, contained on the Site may be the trademarks or registered trademarks of their respective owners.